{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:35:54Z","timestamp":1790501754009,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd008649.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T00:00:00Z","timestamp":1518134400000}}],"reference-count":110,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008649.pub3","type":"journal-article","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T15:46:03Z","timestamp":1518191163000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Inhaled mannitol for cystic fibrosis"],"prefix":"10.1002","author":[{"given":"Sarah J","family":"Nevitt","sequence":"first","affiliation":[{"name":"University of Liverpool; Department of Biostatistics; Block F, Waterhouse Building 1-5 Brownlow Hill Liverpool UK L69 3GL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Thornton","sequence":"additional","affiliation":[{"name":"National Institute for Health and Care Excellence; Centre for Clinical Practice; Level 1A, City Tower, Piccadilly Plaza Manchester UK M1 4BD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare S","family":"Murray","sequence":"additional","affiliation":[{"name":"University of Manchester and University Hospital of South Manchester; Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair; Manchester Academic Health Sciences Centre 46 Grafton Street Manchester UK M13 9NT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Dwyer","sequence":"additional","affiliation":[{"name":"University of Sydney; Discipline of Physiotherapy, Faculty of Health Sciences; Rm No O156, O Block Sydney NSW Australia 2141"},{"name":"University of Sydney; Central Clinical School, Sydney Medical School; Sydney Australia NSW 2006"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,9]]},"reference":[{"key":"10.1002\/14651858.CD008649.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/S1569-1993(12)60216-1","article-title":"Bronchitol (inhaled dry powder mannitol) in adult patients with cystic fibrosis","volume":"11 Suppl 1","author":"Aitken","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0002|cit2","first-page":"S20","article-title":"Phase III study [CF-302] of inhaled dry powder mannitol (Bronchitol\u2122) in cystic fibrosis - results from the 6 month open label phase","volume":"10 Suppl 1","author":"Aitken","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0003|cit3","first-page":"297","article-title":"Efficacy and safety by age group from the phase III studies of bronchitol (inhaled mannitol) in patients with CF","volume":"46 Suppl 34","author":"Aitken","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1164\/rccm.201109-1666OC","article-title":"Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study","volume":"185","author":"Aitken","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0005|cit5","first-page":"299","article-title":"Six-month administration of inhaled mannitol in cystic fibrosis - a safety and efficacy study","volume":"45 Suppl 33","author":"Aitken","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S1569-1993(12)60035-6","article-title":"Inhaled dry powder mannitol in cystic fibrosis (CF): impact on pulmonary exacerbations (PEs) in the Phase III studies (CF-301 & CF-302)","volume":"11 Suppl 1","author":"Bilton","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0007|cit7","first-page":"S20","article-title":"Combined data from the two phase III studies of bronchitol (inhaled dry powder mannitol) in adult cystic fibrosis (CF) patients","volume":"10 Suppl 1","author":"Bilton","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0008|cit8","first-page":"S20","article-title":"Inhaled dry powder mannitol in cystic fibrosis (CF): the microbiology demographics and results from the phase III studies (CF301 and CF302)","volume":"10 Suppl 1","author":"Bilton","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0009|cit9","first-page":"314","article-title":"Improvements in lung function in Pseudomonas colonised patients treated with inhaled dry powder mannitol (Bronchitol\u2122)","volume":"47 Suppl 35","author":"Bilton","year":"2012","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD008649.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jcf.2012.11.002","article-title":"Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis","volume":"12","author":"Bilton","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD008649.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1183\/20734735.021414","article-title":"Optimising inhaled mannitol for cystic fibrosis in an adult population: a review","volume":"11","author":"Flume","year":"2015","journal-title":"Breathe"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0012|cit12","unstructured":"NCT00630812 Long Term Administration of Inhaled Mannitol in Cystic Fibrosis https:\/\/ClinicalTrials.gov\/show\/NCT00630812"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0013|cit13","unstructured":"Pharmaxis Media release: Pharmaxis announces results for second phase III trial of bronchitol in cystic fibrosis www.pharmaxis.com.au\/assets\/documents\/pdf\/2010\/2010_06_22_cf302_top_line_results.pdf 2010"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/S1569-1993(13)60442-7","article-title":"An analysis of medical resource utilisation (MRU) associated with hospitalised pulmonary exacerbations (PulmEx) in the DPM-CF-301 and DPM-CF-302 registration trials of inhaled mannitol (Bronchitol\u00ae) in patients with cystic fibrosis (CF)","volume":"12 Suppl 1","author":"Toward","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/S1569-1993(12)60216-1","article-title":"Bronchitol (inhaled dry powder mannitol) in adult patients with cystic fibrosis","volume":"11 Suppl 1","author":"Aitken","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0016|cit16","first-page":"297","article-title":"Efficacy and safety by age group from the phase III studies of bronchitol (inhaled mannitol) in patients with CF","volume":"46 Suppl 34","author":"Aitken","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S1569-1993(12)60035-6","article-title":"Inhaled dry powder mannitol in cystic fibrosis (CF): impact on pulmonary exacerbations (PEs) in the Phase III studies (CF-301 & CF-302)","volume":"11 Suppl 1","author":"Bilton","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0018|cit18","first-page":"S20","article-title":"Combined data from the two phase III studies of bronchitol (inhaled dry powder mannitol) in adult cystic fibrosis (CF) patients","volume":"10 Suppl 1","author":"Bilton","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0019|cit19","first-page":"S20","article-title":"Inhaled dry powder mannitol in cystic fibrosis (CF): the microbiology demographics and results from the phase III studies (CF301 and CF302)","volume":"10 Suppl 1","author":"Bilton","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0020|cit20","first-page":"314","article-title":"Improvements in lung function in Pseudomonas colonised patients treated with inhaled dry powder mannitol (Bronchitol\u2122)","volume":"47 Suppl 35","author":"Bilton","year":"2012","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD008649.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jcf.2012.11.002","article-title":"Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis","volume":"12","author":"Bilton","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S1569-1993(09)60099-0","article-title":"Randomised, double blind, placebo-controlled phase III study of bronchitol (inhaled powder mannitol) in Cystic Fibrosis CF","volume":"8 Suppl 2","author":"Bilton","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0023|cit23","doi-asserted-by":"crossref","unstructured":"Bilton D Robinson P Cooper P Charlton B Randomised, double-blind, placebo-controlled phase III study of inhaled dry powder mannitol in cystic fibrosis European Respiratory Society Annual Congress; 2009 Sep 12-16; Vienna, Austria 2009","DOI":"10.1016\/S1569-1993(09)60099-0"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0024|cit24","first-page":"286","article-title":"Randomized, double blind, placebo-controlled phase III study of inhaled dry powder mannitol (bronchitol) in CF","volume":"44 Suppl 32","author":"Bilton","year":"2009","journal-title":"Pediatric Pulmonology"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD008649.pub3-BIB0025|cit25","first-page":"A2338","article-title":"Phase III study of inhaled dry powder mannitol (Bronchitol\") in cystic fibrosis results from the 6 month open label phase","volume":"181","author":"Bilton","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"5","key":"10.1002\/14651858.CD008649.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1183\/09031936.00187510","article-title":"Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study","volume":"38","author":"Bilton","year":"2011","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0027|cit27","first-page":"631s","article-title":"Inhaled dry powder mannitol in cystic fibrosis (CF): microbiology results from the 6 month double-blind CF301 study","volume":"36 Suppl","author":"Bilton","year":"2010","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0028|cit28","first-page":"321","article-title":"Long term administration of inhaled dry powder mannitol in CF: results from the open label phase III DPM-CF-301 study","volume":"45 Suppl 33","author":"Bilton","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S1569-1993(10)60080-X","article-title":"Phase III study of inhaled dry powder mannitol (Bronchitol\u2122) in cystic fibrosis - results from the 6 and 12 month open label phase","volume":"9 Suppl 1","author":"Bilton","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0030|cit30","unstructured":"EUCTR2006-004078-28-GB Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis: A Safety and Efficacy Study https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2006-004078-28"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0031|cit31","unstructured":"EUCTR2007-001412-23-IE Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis: A Safety and Efficacy Study https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2007-001412-23"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0032|cit32","unstructured":"EUCTR2008-002740-42-DE Long Term Administration of Inahled Mannitol in Cystic Fibrosis - A Safety and Efficacy Study https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2008-002740-42"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0033|cit33","unstructured":"EUCTR2013-005357-79-CZ Long Term Administration of Inhaled Mannitol in Cystic Fibrosis: A Safety and Efficacy Trial in Adult Cystic Fibrosis Subjects https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2013-005357-79"},{"issue":"1","key":"10.1002\/14651858.CD008649.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1183\/20734735.021414","article-title":"Optimising inhaled mannitol for cystic fibrosis in an adult population: a review","volume":"11","author":"Flume","year":"2015","journal-title":"Breathe"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0035|cit35","unstructured":"NCT00446680 Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis - A Safety and Efficacy Study https:\/\/ClinicalTrials.gov\/show\/NCT00446680"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/S1569-1993(13)60442-7","article-title":"An analysis of medical resource utilisation (MRU) associated with hospitalised pulmonary exacerbations (PulmEx) in the DPM-CF-301 and DPM-CF-302 registration trials of inhaled mannitol (Bronchitol\u00ae) in patients with cystic fibrosis (CF)","volume":"12 Suppl 1","author":"Toward","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0037|cit37","unstructured":"Crossover trial determining the efficacy of dry powder mannitol to improve lung function in subjects aged 6-17 years clinicaltrials.gov\/ct2\/show\/NCT01883531"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0038|cit38","first-page":"273","article-title":"A phase II, randomised, double-blind, placebo-controlled study of dry powder mannitol in children with CF (overall and subgroup analyses)","volume":"51 Suppl 45","author":"Boeck","year":"2016","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S1569-1993(16)30074-1","article-title":"A phase II, randomised, double-blind, placebo-controlled, crossover study of dry powder mannitol in children with cystic fibrosis (CF)","volume":"15 Suppl 1","author":"Boeck","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD008649.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jcf.2017.02.003","article-title":"Inhaled dry powder mannitol in children with cystic fibrosis: a randomised efficacy and safety trial","volume":"16","author":"Boeck","year":"2017","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0041|cit41","unstructured":"EUCTR2012-002699-14-GB Trial of inhaled mannitol in children with cystic fibrosis https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2012-002699-14"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0042|cit42","unstructured":"NCT01883531 Crossover Trial Determining the Efficacy of Dry Powder Mannitol to Improve Lung Function in Subjects Aged 6-17 Years https:\/\/ClinicalTrials.gov\/show\/NCT01883531"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0043|cit43","unstructured":"NTR4453 A trial to determine the efficacy of dry powder mannitol in improving lung function in subjects with Cystic Fibrosis aged six to seventeen years http:\/\/www.trialregister.nl\/trialreg\/admin\/rctview.asp?TC=4453"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0046|cit44","unstructured":"Charlton B Lassig A A randomized, blinded, controlled, crossover study of inhaled, dry powder mannitol (bronchitol) in CF Proceedings of American Thoracic Society Conference; 2006 May 19-24; California, USA 2006 A727"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0044|cit45","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S1569-1993(06)80042-1","article-title":"Inhaled dry powder mannitol (Bronchitol) improves FEV1 in cystic fibrosis","volume":"5 Suppl 1","author":"Charlton","year":"2006","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0045|cit46","doi-asserted-by":"crossref","unstructured":"Charlton B Lassig A CF-201 Study Investigators Inhaled dry powder mannitol (bronchitol) improves FEV1 in cystic fibrosis Proceedings of TSANZ 2006 Annual Scientific Meeting 2006 A11","DOI":"10.1016\/S1569-1993(06)80042-1"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1378\/chest.09-2017","article-title":"Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis","volume":"137","author":"Daviskas","year":"2010","journal-title":"Chest"},{"issue":"6","key":"10.1002\/14651858.CD008649.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1378\/chest.07-2294","article-title":"Inhaled mannitol improves lung function in cystic fibrosis","volume":"133","author":"Jaques","year":"2008","journal-title":"Chest"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0049|cit49","unstructured":"NCT00455130 A Phase 2 Study to Determine the Safety and Efficacy of Inhaled Dry Powder Mannitol in Cystic Fibrosis https:\/\/ClinicalTrials.gov\/show\/NCT00455130"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0050|cit50","unstructured":"ACTRN12612001167853 A study examining the utility of inhaled mannitol as an additional therapy during an admission to hospital for an acute pulmonary exacerbation in children with cystic fibrosis http:\/\/www.anzctr.org.au\/ACTRN12612001167853.aspx"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0051|cit51","first-page":"355","article-title":"Pilot study of inhaled dry powder mannitol in young people with CF hospitalised with pulmonary exacerbation","volume":"47 Suppl 35","author":"Middleton","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0052|cit52","unstructured":"Middleton A Robinson P McKay K Selvadurai H Pilot study of inhaled dry powder mannitol in young people with cystic fibrosis hospitalised with pulmonary exacerbation Department of Respiratory Medicine, Children's Hospital at Westmead (www.thoracic.org.au) (accessed 21 Oct 2014) 2014"},{"issue":"2","key":"10.1002\/14651858.CD008649.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1183\/09031936.00137814","article-title":"A pilot study of inhaled dry-powder mannitol during cystic fibrosis-related pulmonary exacerbation [letter]","volume":"45","author":"Middleton","year":"2015","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0054|cit54","unstructured":"EUCTR2004-001888-21-GB A cross-over comparative study of inhaled mannitol, alone and in combination with daily rhDNase, in children with cystic fibrosis - Inhaled Mannitol in Cystic Fibrosis https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2004-001888-21"},{"issue":"1","key":"10.1002\/14651858.CD008649.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/thx.2009.116970","article-title":"Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial","volume":"65","author":"Minasian","year":"2010","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0056|cit56","first-page":"301","article-title":"A crossover comparative study of inhaled mannitol, alone and in combination with daily rhDNase, in children with cystic fibrosis","volume":"43 Suppl 31","author":"Minasian","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0057|cit57","unstructured":"NCT00117208 Comparison of Inhaled Mannitol and rhDNase in Children With Cystic Fibrosis https:\/\/ClinicalTrials.gov\/show\/NCT00117208"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0058|cit58","first-page":"280","article-title":"Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis","volume":"26 Suppl 17","author":"Robinson","year":"1998","journal-title":"Pediatric Pulmonology"},{"issue":"3","key":"10.1002\/14651858.CD008649.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1034\/j.1399-3003.1999.14c30.x","article-title":"The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study","volume":"14","author":"Robinson","year":"1999","journal-title":"European Respiratory Journal"},{"issue":"6","key":"10.1002\/14651858.CD008649.pub3-BIB0060|cit60","first-page":"484","article-title":"The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study","volume":"29","author":"Robinson","year":"2000","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0061|cit61","unstructured":"NCT00251056 Mannitol Dose Response Study in Cystic Fibrosis https:\/\/ClinicalTrials.gov\/show\/NCT00251056"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0062|cit62","first-page":"13B","article-title":"A dose response trial of inhaled mannitol in patients with cystic fibrosis","volume":"17","author":"Teper","year":"2010","journal-title":"Canadian Respiratory Journal"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcf.2010.08.020","article-title":"Inhaled mannitol in patients with cystic fibrosis: a randomised open-label dose response trial","volume":"10","author":"Teper","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0064|cit64","unstructured":"A safety and efficacy trial of inhaled mannitol in adult cystic fibrosis subjects clinicaltrials.gov\/ct2\/show\/NCT02134353"},{"issue":"8","key":"10.1002\/14651858.CD008649.pub3-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1164\/rccm.200701-160UP","article-title":"Update in cystic fibrosis 2006","volume":"175","author":"Accurso","year":"2007","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"3 Pt 1","key":"10.1002\/14651858.CD008649.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1164\/ajrccm.156.3.9701113","article-title":"A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol","volume":"156","author":"Anderson","year":"1997","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0067|cit67","first-page":"289","article-title":"Predicting sustained response to Bronchitol\u2122 treatment in patients with cystic fibrosis","volume":"47 Suppl 35","author":"Bilton","year":"2012","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD008649.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jcf.2012.11.002","article-title":"Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis","volume":"12","author":"Bilton","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD008649.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1183\/09031936.03.00113403","article-title":"Evidence of mast cell activation and leukotriene release after mannitol inhalation","volume":"22","author":"Brannan","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0070|cit70","first-page":"356","article-title":"Inhaled mannitol as an adjunct to airway clearance therapy in an adult cystic fibrosis population and clinical lessons learned","volume":"48 Suppl 36","author":"Button","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1016\/S1569-1993(13)60335-5","article-title":"Clinical impact of inhaled mannitol in an adult cystic fibrosis population","volume":"12 Suppl 1","author":"Button","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD008649.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.prrv.2007.02.008","article-title":"Other mucoactive agents for cystic fibrosis","volume":"8","author":"Bye","year":"2007","journal-title":"Paediatric Respiratory Reviews"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0073|cit73","unstructured":"Canadian Cystic Fibrosis Foundation Report of the Canadian Patient Data Registry Canadian Patient Data Registry 2002"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0074|cit74","unstructured":"Cystic Fibrosis Foundation National Patient Registry Annual Data Report 2000 Cystic Fibrosis Foundation, Bethesda, Maryland 2000"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0075|cit75","unstructured":"Cystic Fibrosis Foundation National Patient Registry Annual Data Report 2005 Cystic Fibrosis Foundation, Bethesda, Maryland 2005"},{"issue":"11","key":"10.1002\/14651858.CD008649.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1183\/09031936.97.10112449","article-title":"Inhalation of dry powder mannitol increases mucociliary clearance","volume":"10","author":"Daviskas","year":"1997","journal-title":"European Respiratory Journal"},{"issue":"2","key":"10.1002\/14651858.CD008649.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1378\/chest.119.2.414","article-title":"The 24-h effect of mannitol on the clearance of mucus in patients with bronchiectasis","volume":"119","author":"Daviskas","year":"2001","journal-title":"Chest"},{"issue":"6","key":"10.1002\/14651858.CD008649.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1183\/09031936.02.00301502","article-title":"Effects of terbutaline in combination with mannitol on mucociliary clearance","volume":"20","author":"Daviskas","year":"2002","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD008649.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1440-1843.2005.00659.x","article-title":"Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum","volume":"10","author":"Daviskas","year":"2005","journal-title":"Respirology"},{"issue":"4","key":"10.1002\/14651858.CD008649.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1378\/chest.09-2017","article-title":"Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis","volume":"137","author":"Daviskas","year":"2010","journal-title":"Chest"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0081|cit81","unstructured":"Deeks J Higgins J Altman D Chapter 9 Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD008649.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000029453","article-title":"Pathogenesis of lung disease in cystic fibrosis","volume":"67","author":"Dinwiddie","year":"2000","journal-title":"Respiration"},{"issue":"3","key":"10.1002\/14651858.CD008649.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1183\/09031936.00099506","article-title":"Cystic fibrosis mortality and survival in the UK 1947-2003","volume":"29","author":"Dodge","year":"2007","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD008649.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0085|cit85","unstructured":"European Medicines Agency Bronchitol www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/001252\/human_med_001475.jsp&mid=WC0b01ac058001d124"},{"issue":"1","key":"10.1002\/14651858.CD008649.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1183\/20734735.021414","article-title":"Optimising inhaled mannitol for cystic fibrosis in an adult population","volume":"11","author":"Flume","year":"2015","journal-title":"Breathe"},{"issue":"10","key":"10.1002\/14651858.CD008649.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis","volume":"331","author":"Fuchs","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD008649.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1136\/thorax.55.11.946","article-title":"Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis","volume":"55","author":"Gee","year":"2000","journal-title":"Thorax"},{"issue":"7414","key":"10.1002\/14651858.CD008649.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0090|cit90","unstructured":"Higgins JPT Altman DG (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0091|cit91","volume-title":"Cystic Fibrosis","author":"Hodson","year":"2000"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0092|cit92","unstructured":"Jones AP Riley R Williamson PR Whitehead A Meta-analysis of longitudinal data Royal Statistical Society Annual Conference 2005"},{"issue":"2","key":"10.1002\/14651858.CD008649.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1053\/prrv.2000.0029","article-title":"Cystic fibrosis: basic science","volume":"1","author":"McAuley","year":"2000","journal-title":"Paediatric Respiratory Reviews"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0094|cit94","unstructured":"National Institute for Health and Clinical Excellence Mannitol dry powder for inhalation for treating cystic fibrosis (TA266) National Institute for Health and Clinical Excellence 2012"},{"issue":"6","key":"10.1002\/14651858.CD008649.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0096|cit96","unstructured":"Quittner A (Department of Psychology Miami College of Arts and Sciences USA) [personal communication] Conversation with: T Dwyer (Sydney Medical School, Australia) February 2015"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(03)12567-6","article-title":"Cystic Fibrosis","volume":"361","author":"Ratjen","year":"2003","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0098|cit98","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"3","key":"10.1002\/14651858.CD008649.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/thorax.56.3.237","article-title":"Cystic Fibrosis","volume":"56","author":"Robinson","year":"2001","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2008.09.007","article-title":"High treatment burden in adults with cystic fibrosis: challenges to disease self-management","volume":"8","author":"Sawicki","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0101|cit101","unstructured":"Scottish Medicines Consortium Mannitol, 400mg, inhalation powder, hard capsule (Bronchitol\u00ae) SMC No. (837\/13) www.scottishmedicines.org.uk\/files\/advice\/inhaled_mannitol_Bronchitol_FINAL_January_2013_for_website.pdf"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0102|cit102","unstructured":"Sterne J Egger M Moher D Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook forSystematic Reviews of Interventions Version 5.1 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"10","key":"10.1002\/14651858.CD008649.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/thorax.57.10.841","article-title":"Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis","volume":"57","author":"Suri","year":"2002","journal-title":"Thorax"},{"issue":"7","key":"10.1002\/14651858.CD008649.pub3-BIB0104|cit104","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007168.pub3","article-title":"Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis","author":"Tam","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD008649.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/0091-6749(83)90626-7","article-title":"Effects of chemical mediators of anaphylaxis on ciliary function","volume":"72","author":"Wanner","year":"1983","journal-title":"Journal of Clinical Immunology"},{"issue":"2","key":"10.1002\/14651858.CD008649.pub3-BIB0106|cit106","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001506.pub3","article-title":"Nebulised hypertonic saline for cystic fibrosis","author":"Wark","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD008649.pub3-BIB0107|cit107","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002996.pub2","article-title":"Inhaled hyperosmolar agents for bronchiectasis","author":"Wills","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD008649.pub3-BIB0108|cit108","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001127.pub3","article-title":"Dornase alfa for cystic fibrosis","author":"Yang","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008649.pub3-BIB0109|cit109","unstructured":"Zorginstituut Nederland Mannitol (Bronchitol\u00ae) for the indication 'adult patients with cystic fibrosis'. Pharmacotherapeutic report, summary www.zorginstituutnederland.nl\/binaries\/content\/documents\/zinl-www\/documenten\/publicaties\/publications-in-english\/2014\/1407-mannitol-bronchitol-for-the-indication-adult-patients-with-cystic-fibrosis-pharmacotherapeutic-report-summary\/Mannitol+(Bronchitol)+for+the+indication+'adult+patients+with+cystic+fibrosis'+(Pharmacotherapeutic+report,+summary).pdf"},{"issue":"10","key":"10.1002\/14651858.CD008649.pub3-BIB0110|cit110","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008649.pub2","article-title":"Inhaled mannitol for cystic fibrosis","author":"Nolan","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd008649.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD008649.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:22:16Z","timestamp":1628547736000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD008649.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,2,9]]},"references-count":110,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008649.pub3","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD008649.pub4","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,9]]}}}